PB2072 Denecimig (Mim8) tiered dosing achieves consistent exposure and bleed control in phase 3 FRONTIER studies

Denecimig (Mim8) is a next-generation, activated factor VIII (FVIII) mimetic bispecific antibody in development as prophylaxis for patients with haemophilia A (HA) with or without FVIII inhibitors. Denecimig is administered subcutaneously using tiered dosing determined by weight range and chosen dosing frequency (once-every-month, once-every-two-weeks, once-every-week).